MarketCap
Facebook
X
TelegramQuarterly report 2022-Q4
added 02-09-2023
Meridian Bioscience Interest Expense 2011-2026 | VIVO
Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.Includes:
- Interest on bank loans
- Interest on corporate bonds
- Interest on leases
- Interest on credit lines and overdrafts
High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.
Low interest expenses with high profits are a sign of financial stability.
Annual Interest Expense Meridian Bioscience
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.19 M | 1.88 M | 2.63 M | 1.94 M | 1.52 M | 1.64 M | 897 K | -1.02 M | -309 K | 4 K | 378 K | 352 K |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 2.63 M | -1.02 M | 926 K |
Quarterly Interest Expense Meridian Bioscience
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 148 K | - | - | 341 K | 372 K | - | 444 K | 472 K | 534 K | 2 M | 703 K | 534 K | 767 K | 1.16 M | 448 K | 767 K | 363 K | 1.15 M | 375 K | 363 K | 395 K | 1.24 M | 407 K | 395 K | 423 K | 470 K | 427 K | 423 K | 96 K | -892 K | -99 K | 96 K | -582 K | -505 K | -257 K | -582 K | -220 K | 225 K | -160 K | -220 K | 128 K | 304 K | 31 K | 128 K | 316 K | 357 K | 36 K | 316 K |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 2 M | -892 K | 303 K |
Interest Expense of other stocks in the Diagnostics research industry
| Issuer | Interest Expense | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Agilent Technologies
A
|
81 M | $ 115.35 | -2.33 % | $ 35.1 B |  USA |
 |
Anixa Biosciences
ANIX
|
500 K | $ 2.81 | -2.7 % | $ 91.2 K | USA |
 |
Centogene N.V.
CNTG
|
8.42 M | - | -6.23 % | $ 30.6 M |  Germany |
|
Akumin
AKU
|
118 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Check-Cap Ltd.
CHEK
|
13 K | - | - | $ 9.42 M |  Israel |
 |
Aspira Women's Health
AWH
|
106 K | - | -6.19 % | $ 10.5 M | USA |
 |
Burning Rock Biotech Limited
BNR
|
1.54 M | $ 22.48 | -1.58 % | $ 234 M |  China |
 |
Bioventus
BVS
|
-1.45 M | $ 8.45 | -7.14 % | $ 563 M | USA |
 |
Celcuity
CELC
|
2.11 M | $ 114.85 | -0.34 % | $ 4.53 B | USA |
 |
Castle Biosciences
CSTL
|
1 K | $ 27.23 | -2.44 % | $ 756 M | USA |
 |
Charles River Laboratories International
CRL
|
-22.6 M | $ 175.23 | -3.37 % | $ 8.69 B | USA |
 |
DermTech
DMTK
|
-355 K | - | -11.32 % | $ 2.94 M | USA |
 |
Co-Diagnostics
CODX
|
106 K | - | - | $ 79.8 M | USA |
 |
Fulgent Genetics
FLGT
|
561 K | $ 14.59 | 2.41 % | $ 441 M | USA |
 |
Accelerate Diagnostics
AXDX
|
235 K | - | -61.36 % | $ 2.46 M | USA |
 |
Global Cord Blood Corporation
CO
|
6.27 M | - | - | $ 399 M | China |
 |
Genetic Technologies Limited
GENE
|
15.2 K | - | - | $ 7.1 B |  Australia |
|
Biodesix
BDSX
|
8.26 M | $ 18.61 | 17.37 % | $ 2.41 B | USA |
 |
Biocept
BIOC
|
316 K | - | -13.05 % | $ 7.29 M | USA |
 |
Illumina
ILMN
|
-292 M | $ 124.76 | -2.71 % | $ 19.8 B | USA |
 |
IQVIA Holdings
IQV
|
729 M | $ 175.33 | -1.8 % | $ 30.1 B | USA |
 |
BioNano Genomics
BNGO
|
-10.1 M | $ 1.11 | -1.36 % | $ 1.41 M | USA |
 |
Heska Corporation
HSKA
|
4.19 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
857 K | - | -20.0 % | $ 1.06 M | USA |
 |
Quest Diagnostics Incorporated
DGX
|
26 M | $ 199.8 | -2.07 % | $ 22.2 B | USA |
 |
Danaher Corporation
DHR
|
-222 M | $ 195.75 | -2.99 % | $ 140 B | USA |
 |
IDEXX Laboratories
IDXX
|
29.8 M | $ 607.19 | -1.9 % | $ 48.8 B | USA |
 |
Exact Sciences Corporation
EXAS
|
18.6 M | $ 103.5 | 0.17 % | $ 19.5 B | USA |
 |
DarioHealth Corp.
DRIO
|
-31 K | $ 9.69 | -3.0 % | $ 275 M | Israel |
 |
Laboratory Corporation of America Holdings
LH
|
224 M | $ 269.52 | -2.34 % | $ 22.4 B | USA |
 |
DexCom
DXCM
|
177 M | $ 68.5 | -3.1 % | $ 26.7 B | USA |
 |
QIAGEN N.V.
QGEN
|
-739 K | - | - | $ 10.6 B |  Niderland |
 |
ICON Public Limited Company
ICLR
|
337 M | $ 107.08 | -3.19 % | $ 8.83 B |  Irlanda |
 |
Lantheus Holdings
LNTH
|
31.3 M | $ 72.86 | -4.53 % | $ 4.92 B | USA |
 |
CareDx, Inc
CDNA
|
524 K | $ 17.91 | -4.48 % | $ 954 M | USA |
 |
Chembio Diagnostics
CEMI
|
2.94 K | - | 0.22 % | $ 16.8 M | USA |
 |
Mettler-Toledo International
MTD
|
68.5 M | $ 1 215.85 | -3.66 % | $ 25.1 B |  Schweiz |
 |
Myriad Genetics
MYGN
|
800 K | $ 5.15 | 0.29 % | $ 477 M | USA |
 |
NeoGenomics
NEO
|
296 K | $ 8.92 | -2.3 % | $ 1.14 B | USA |
 |
National Research Corporation
NRC
|
-95 K | $ 14.48 | 3.13 % | $ 324 M | USA |
 |
Guardant Health
GH
|
-10.5 M | $ 91.56 | -1.1 % | $ 11.5 B | USA |
 |
Natera
NTRA
|
9.32 M | $ 196.94 | -0.1 % | $ 19.4 B | USA |
 |
Motus GI Holdings
MOTS
|
211 | - | -34.28 % | $ 263 K | Israel |
 |
OPKO Health
OPK
|
207 M | $ 1.18 | 0.43 % | $ 819 M | USA |
 |
Enzo Biochem
ENZ
|
494 K | - | -8.98 % | $ 14.8 K | USA |